With the continuous rise in chronic diseases such as cancer, cardiovascular diseases, and neurological disorders, the global demand for precise and efficient diagnostic tools has sharply increased. According to a recent report by research firm DelveInsight, the global AI medical imaging market is expected to surge from $1.6 billion in 2024 to approximately $13 billion by 2032, with a compound annual growth rate of about 29%. This growth momentum is driven by technological breakthroughs, government support, and increased capital investment.

The report indicates that the rapid advancement of deep learning, machine learning, and computer vision is significantly improving the accuracy and efficiency of image diagnosis. AI not only helps doctors detect subtle lesions but also optimizes treatment decisions through predictive analysis, greatly reducing diagnosis time and improving patient outcomes.

From an industry perspective, international giants such as GE HealthCare, Siemens Healthineers, Philips, Fujifilm, Canon Medical, IBM Watson Health, Aidoc, and Qure.ai are actively expanding their AI imaging businesses and accelerating innovation through mergers and collaborations. The competition is shifting from "equipment intelligence" to "system collaboration," with software algorithms and clinical integration becoming the new focus.

North America continues to dominate this field, accounting for 42% of the market share in 2024. The United States, with its strong medical infrastructure, AI R&D investments, and FDA's accelerated approval mechanism, has become the center of AI imaging applications globally. Europe, represented by Germany, the UK, and France, is accelerating the transition to digital healthcare and the implementation of precision medicine; while the Asia-Pacific region is experiencing the fastest growth, with China, Japan, South Korea, and India heavily investing in AI diagnostic infrastructure to promote the popularization of smart healthcare.

In addition, government funding and regulatory reforms are also driving the industry forward. Countries are launching funding programs and innovative policies to encourage the development and application of AI medical imaging. For example, the U.S. FDA recently approved multiple AI imaging tools, including RapidAI Lumina3D and Nerveblox systems, providing strong endorsement for the industry.

In the future, AI medical imaging is expected to become a core component of the healthcare system, evolving from "assisting doctors" to "collaborative diagnosis."

Key Points:

🧠 The global AI medical imaging market is expected to reach $13 billion by 2032, with an annual growth rate of around 29%.

🏥 North America leads, with the Asia-Pacific region growing the fastest; leading companies are accelerating the deep integration of algorithms and clinical practice.

💰 Technological innovation and government funding are driving forces, and AI is moving from an auxiliary tool to a core diagnostic system.